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Abstract
Background: Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate
ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor
cells from intracellular reactive oxygen species (ROS)-associated apoptosis. However, the function of TIGAR in
glycolysis and survival of acute myeloid leukemia cells remains unclear.
Methods: We analyzed TIGAR expression in cytogenetically normal (CN-) AML patients and the correlations
with clinical and biological parameters. In vivo and in vitro, we tested whether glycolysis may induce TIGAR
expression and evaluated the combination effect of glycolysis inhibitor and TIGAR knockdown on human
leukemia cell proliferation.
Results: High TIGAR expression was an independent predictor of poor survival and high incidence of relapse in adult
patients with CN-AML. TIGAR also showed high expression in multiple human leukemia cell lines and knockdown of
TIGAR activated glycolysis through PFKFB3 upregulation in human leukemia cells. Knockdown of TIGAR inhibited the
proliferation of human leukemia cells and sensitized leukemia cells to glycolysis inhibitor both in vitro and in vivo.
Furthermore, TIGAR knockdown in combination with glycolysis inhibitor 2-DG led leukemia cells to apoptosis. In
addition, the p53 activator Nutlin-3α showed a significant combinational effect with TIGAR knockdown in leukemia
cells. However, TIGAR expression and its anti-apoptotic effects were uncoupled from overexpression of exogenous p53
in leukemia cells.
Conclusions: TIGAR might be a predictor of poor survival and high incidence of relapse in AML patients, and the
combination of TIGAR inhibitors with anti-glycolytic agents may be novel therapies for the future clinical use in
AML patients.
Keywords: TIGAR, Glycolysis, Acute myeloid leukemia, Apoptosis, Survival
* Correspondence: Yaoyu.chen@njmu.edu.cn
†Equal contributors
Department of Hematology, The First Affiliated Hospital of Nanjing Medical
University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029,
China
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Qian et al. Journal of Hematology & Oncology  (2016) 9:128 
DOI 10.1186/s13045-016-0360-4
Background
“Warburg effect” is a fundamental metabolic change
during malignant transformation in human cancer
[1–3]. Under this condition, most cancer cells predomin-
antly produced energy by a high rate of glycolysis and
showed an elevated fructose-2, 6-bisphosphate (Fru-2,6-P2)
levels [1, 2]. These metabolic pathways underpinning
the abnormal growth, proliferation, and survival of
cancer cells were modulated by a couple of glycolytic
enzymes [4, 5]. As well as solid tumors, human
leukemia cells also exhibited the increased rating of
aerobic glycolysis and generated ATP as the main en-
ergy source [5, 6].
Many oncogenes and tumor suppressors regulated the
expression of glycolytic enzymes [7]. TIGAR, a p53-
inducible glycolysis and apoptosis regulator, has a func-
tional sequence similar to the bisphosphatase domain
(FBPase-2) of 6-phosphofructo-2-kinase (PFK-2/FBPase)
[8]. The functions of TIGAR were potentially relevant to
cancer initiation and progression [8]. On the one hand,
high expression of TIGAR in human cancer may protect
cancer cells from cell death [9]. On the other hand,
TIGAR inhibited glycolysis through Fru-2,6-P2 degrad-
ation, directing metabolism into the pentose phosphate
pathway (PPP) to produce NADPH and glutathione
(GSH) as anti-oxidants, and ribose-5-phosphate for nu-
cleotide synthesis [10]. TIGAR also showed high expres-
sion among several cancer types, including human colon
tumors [4], breast cancer [11, 12], and glioblastoma [13–
15], which suggesting that upregulated TIGAR expres-
sion may support, rather than inhibit, cancer develop-
ment [1]. High TIGAR expression correlated with the
increased tumor survival/burden, while TIGAR depletion
promoted the apoptosis rate of cancer cells [12, 16–18].
TIGAR depletion also enhanced the epirubicin-induced
activation of autophagy [19]. In addition, knockdown of
TIGAR gene increased Fru-2,6-P2 and reactive oxygen
species (ROS) levels and decreased GSH levels in glio-
blastoma cells [14].
However, the function of TIGAR in human chronic or
acute leukemia remains unknown. In this study, we
showed that the expression of TIGAR in patients with cy-
togenetically normal acute myeloid leukemia (CN-AML)
correlated with the clinical features and outcomes.
The high TIGAR expression in AML might be an in-
dependent prognostic factor for survival in patients
with CN-AML. Knockdown of TIGAR inhibited the
proliferation of human leukemia cells and sensitized
leukemia cells to glycolysis inhibitor 2-deoxy-D-glucose
(2-DG) both in vitro and in vivo, which may be due
to increased apoptosis rate of leukemia cells. Our
results suggested that TIGAR might be a predictor of




One hundred sixteen patients, aged ≥14 years, with pre-
viously untreated CN-AML attended this study. All pa-
tients were diagnosed for AML. All those patients had
complete clinical data available, and enough cryopre-
served bone marrow (BM) samples taken at diagnosis,
for analysis. Twenty health donors attended the study as
the control. Among 116 patients, 109 patients were
treated and followed up (until death or for a period of
up to 53 months, between October 2007 and February
2013) at the Hematology Department of the First
Affiliated Hospital of Nanjing Medical University (Nanjing,
People’s Republic of China). All 109 patients received
cytarabine-based intensive induction and consolidation
chemotherapy. This study was approved by the institu-
tional review board of the First Affiliated Hospital of
Nanjing Medical University and carried out in accord-
ance with the Declaration of Helsinki. All patients and
normal donors provided written informed consent for
this study.
Cytogenetic and mutation analyses
BM cells were harvested directly or after 1–3 days of un-
stimulated culture, as described previously [1]. Meta-
phase cells were banded via an improved heat treatment
and Giemsa R-banding method. The diagnosis of a nor-
mal karyotype was based on conventional cytogenetic
examination of at least 20 metaphases. Genomic DNA
was isolated from BM specimens. Mutation analysis of
five relevant molecular marker genes (NPM1, CEBPA,
FLT3-ITD, KIT, and p53) was carried out as described
previously [20, 21].
Outcome measures
The primary endpoints were overall survival (OS; dur-
ation from diagnosis to death from any cause), disease-
free survival (DFS; time from achievement of complete
remission (CR) until relapse or death), and morphologic
leukemia relapse (hematologic and/or extramedullary).
For analyses of DFS, failure was considered to be clinical
or hematologic relapse or death from any cause; patients
alive and in CR were censored at last follow-up. For ana-
lyses of OS, failure was considered to be death from any
cause; patients alive were censored at the date of last
contact.
Western blot
Cells were lysed in RIPA buffer containing Halt Protease
and Phosphatase Inhibitor Mixture (Thermo Scientific).
Lysates were spun at 16,000×g at 4 °C for 30 min and nor-
malized for protein concentration. Western blotting was
performed as follows: total tumor lysates were separated
by SDS/PAGE and electrotransferred to nitrocellulose
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membrane (Invitrogen). Membranes were blocked in PBS
and 0.1% (vol/vol) Tween-20 (PBS-T) and 4% (wt/vol)
nonfat dry milk (Bio-Rad) for 1 h on a shaker at room
temperature. Primary antibodies were added to the block-
ing solution at 1:500 (TIGAR; Abcam, 37910), 1:500
(GSH; Abcam, 19534), 1:500 (PFKFB3; Abcam, 96699),
and 1:1000 (Actin; Abcam, 3280) dilutions and incubated
overnight and a rocker at 4 °C. Immunoblottings were
washed three times, 5 min each with PBS-T, and second-
ary antibody was added at 1:10,000 dilution into PBS-T
milk for 1 h on a shaker at room temperature. After
several washes, enhanced chemiluminescence (ECL) reac-
tions were performed according to the manufacturer’s
recommendations (SuperSignal West Dura Extended
Duration Substrate; Thermo Scientific).
Quantitative real-time reverse transcription PCR
The relative TIGAR mRNA expression was determined
by comparing the TIGAR expression relative to GAPDH.
The TIGAR expression was compared among other 116
AML patients by using the real-time quantitative PCR
and the 2−ΔΔCt method. The ΔCt of health donor was
used as a control value for each AML patient. Patients
with TIGAR expression values above the median of all
patients were defined as having high TIGAR expression
(TIGARhigh), while all other patients were considered to
have low TIGAR expression (TIGARlow).
Cell lines
HL-60, K562, Jurkat, and NB-4 cells (ATCC, USA) were
cultured in RPMI1640 (GIBCO, USA), 10% fetal bovine
serum, 2 mM L-glutamine, 50 U/ml penicillin, and
50 μg/ml streptomycin. All these cell lines were authen-
ticated and tested for mycoplasma contamination. Cells
were treated with 400 μM cobalt chloride (CoCl2)
(Amresco, USA) for 48 h to induce glycolysis, or with
1 mg/ml 2-deoxy-D-glucose (2-DG) (Sigma-Aldrich,
USA) for 48 h to suppress glycolysis.
Short hairpin RNA and gene overexpression constructs
To inhibit TIGAR mRNA expression, small interfering
RNAs (siRNA) matching nucleotide region 565–583
(TTAGCAGCCAGTGTCTTAG, TIGAR siRNA) of
the human TIGAR cDNA sequence were synthesized
as an antisense, and a scramble sequence (TTACCG
AGACCGTACGTAT) was synthesized as a control.
The TIGAR and scramble sequence were further
cloned into the pSRL-SIH1-H1-Puro lentivirus vector.
TIGAR and p53 cDNA was ordered and cloned into
pcDNA3 vector.
Lentivirus and infection
Lentiviral supernatants were generated according to the
established protocol. A medium was replaced and after
24 h. The scramble shRNA or TIGAR shRNA lentivirus
transduced leukemia cells were selected by puromycin
for 48 h and used.
Measurement of apoptosis and cell death
HL-60 cells and NB-4 with scramble or shRNA-TIGAR
were treated with CoCl2 or 2-DG for 48 h. After treat-
ment, aliquots were removed and counted by trypan
blue (Sigma-Aldrich) exclusion in duplicate. Apoptosis
was quantified by phosphatidylserine externalization.
Briefly, the samples were stained with Annexin V-FITC
and propidium iodide (PI) or 7AAD according to the
manufacturer’s recommendations. Flow cytometry (FACS
Calibur; BD Biosciences) enabled the distinction of viable
cells (Annexin V-FITC−, PI−) from those in apoptosis
(Annexin V-FITC+, PI−) [22]. Annexin V-FITC−, PI+
population was defined as dead/necrosis cells. Except
where documented, all results were shown as a mean plus
or minus SD.
Measurement of intracellular ROS
Human leukemia cells in 24-well plates were incubated
at 37 °C for 30 min with 500 μl of 10 μmol/L DCFH-DA
probe (S0033; Beyotime Institute of Biotechnology,
Haimen, China), with shaking every 5 min. The cells
were then washed with PBS (three times, 5 min each) to
remove any remaining extracellular DCFH-DA probe
[23]. The fluorescence intensity, representing cellular
ROS levels, was detected using a Gemini XPS fluori-
metric microplate reader (MolecularDevices, Shanghai,
China), with excitation and emission wavelengths of 488
and 525 nm, respectively.
Measurement of intracellular F2,6BP
HL-60 cells were centrifuged at 200×g, resuspended in
20 volumes of 0.05 N NaOH and then one volume of
0.1 N NaOH to obtain a pH >11, vortexed for 10 s, incu-
bated at 80 °C for 5 min and cooled in an ice bath. Cell
extracts were neutralized to pH 7.2 with ice-cold acetic
acid in the presence of 20 mM HEPES. Samples were in-
cubated at 25 °C for 2 min in the following assay mix-
ture: 50 mM Tris, 2 mM Mg2+, 1 mM F6P, 0.15 mM
NAD, 10 u/l PPi-dependent PFK1, 0.45 kU/l aldolase,
5 kU/l triosephosphate isomerase, and 1.7 kU/l glycerol-
3-phoshate dehydrogenase (Sigma). 0.5 mM pyrophos-
phate was added and the rate of change in absorbance
(OD = 339 nm) per min was followed for 5 min. F2,6BP
was calculated based on a calibration curve produced by
measuring 0.1 to 1 pmol of F2,6BP (Sigma) and normal-
ized to total cellular protein.
Tumor xenografts
Mice were maintained and handled in accordance with
Nanjing Medical University Animal Care and Use
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Committee protocols and regulations. HL-60 cells
with scramble shRNA or shRNA against TIGAR
were cultured in RPMI1640 supplemented with 10%
FBS. BALB/c (nu/nu) nude female mice (6–8 weeks
old, n = 10) were inoculated with 1 × 106 cells
through i.p. injection. The human leukemia cells
were measured by FACS. Drug treatment started
7 days after implant. Those animals were assigned
randomly to different groups. Animals received ve-
hicle (5% dextrose, 10 ml/kg, orally, once a day) or
2-DG (2 g/kg, orally, once a day) for the duration of
the study. Data were shown as mean ± SD, and differences
are considered statistically significant at p < 0.05 by
Student’s t test.
Statistical analyses
Data were analyzed using SPSS version 16.0 (IBM, USA).
Statistical significance was considered at P < 0.05. Pos-
sible differences between continuous variables were
analyzed using Student’s t test. Data are represented
as mean with SD as error bars unless otherwise men-
tioned. No power analysis was used to pre-determine
sample size. Chi-square or Fisher’s exact tests were
performed to compare incidences. The Kaplan-Meier
method was employed to estimate survival prob-
abilities, and the log-rank test for univariate com-
parisons. The probabilities of relapse were calculated
by cumulative incidence curves. The associations be-
tween TIGAR expression or other characteristics and
OS were studied using a Cox’s proportional hazards
regression model.
Results
TIGAR upregulation is associated with poor prognosis in
AML patients
The expression of TIGAR was evaluated in healthy
donor and primary AML samples by real-time PCR.
TIGAR was significantly upregulated in primary AML
blood cells in comparison with healthy human blood
cells (Fig. 1a). The upregulation of TIGAR was also
shown in CD34+ BM cells from healthy donor or AML
patients by western blotting (Fig. 1b). To understand the
expression of TIGAR in the population of AML patients,
we collected 116 AML patients and measured the
TIGAR expression in BM cells from AML patients by
real-time PCR. Those patients from TIGARhigh group
showed a robust upregulation of TIGAR gene in BM
cells in comparison with patients from TIGARlow group
(Fig. 1c).
To investigate whether upregulation of TIGAR was
associated with prognosis in AML patients, we further
analyzed the association of TIGAR expression with prog-
nosis in those AML patients with median age 48 years
(range, 12–86 years). Eighty-two (70.7%) patients were
aged <60 years (“younger patients”), and 34 (29.3%) pa-
tients were aged ≥60 years (“older patients”). The clinical
characteristics of these patients were shown in Table 1.
There was no significant difference between the two
groups for most clinical characteristics, including white
blood cell count, hemoglobin level, platelet count, % per-
ipheral blood (PB) blasts, and % BM blasts. In addition,
no association was found between TIGAR expression
and mutations in the NPM1, FLT3-ITD, c-KIT, or P53
Fig. 1 TIGAR upregulation was associated with poor prognosis in AML patients. a Real-time PCR showed that TIGAR mRNA was significantly
upregulated in PB cells from three AML patients in comparison with three healthy donors. The TIGAR expression was normalized to 1000 copies
of GAPDH expression. b Western blotting analysis showed that the protein expression of TIGAR protein was increased in CD34+ BM cells from
AML patient versus healthy donor. c Real-time PCR showed that the relative expression of TIGAR mRNA between TIGARlow and TIGARhigh patients.
The result represented as mean with S.E. as error bars. d–f Patients from TIGARlow group presented significantly longer overall survival (OS) (P = 0.021)
(d) and disease-free survival (DFS) (P = 0.028) (e) and lower cumulative incidence of relapse (P = 0.044) (f) than patients from TIGARhigh group
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genes; however, the patients from TIGARlow group were
more prone to have high CEBPA expression (P = 0.0453).
The median survival of the entire cohort was 25 months
(2–69 months). The 109 patients from TIGARhigh and
TIGARlow groups had a similar rate of complete re-
sponse (CR) (74.5 vs. 72.7%). However, the 55 patients
from TIGARlow group showed a significantly longer OS
(P = 0.021) (Fig. 1d) and disease-free survival (DFS) (P =
0.028) (Fig. 1e) and a lower cumulative incidence of re-
lapse (P = 0.044) (Fig. 1f ) than patients from TIGARhigh
group. The 54 patients from TIGARhigh group also
showed a trend towards a higher relapse rate than those
from TIGARlow group (29.1 vs. 18.2%), although statis-
tical significance was not reached.
A multivariate analysis was conducted to determine
the prognostic significance of TIGAR expression with
consideration of other known risk factors, including age,
white blood cell count (WBC), and different chemother-
apy regimens (Table 2). We found that low TIGAR
expression was associated with a reduction in the risk of
death (P = 0.023; Table 3). Younger age was also associ-
ated with longer survival (P = 0.025, Table 3). In addition,
a high proportion of BM blasts (P = 0.058, Table 3) and
chemotherapy (P = 0.078, Table 3) may be also involved
into longer survival of AML patients.
TIGAR showed a high expression in human leukemia cell
lines and glycolysis induced the expression of TIGAR
Because p53 null or mutant human tumor cell lines
showed a significant high basal level of TIGAR protein
expression regulated by p53-independent mechanisms
[8], we decided to test the expression of TIGAR in sev-
eral established human p53 null or mutant acute
leukemia cell lines to identify the leukemia cell line with
high expression of TIGAR. Four different acute leukemia
cell lines: HL-60, K562, Jurkat, and NB-4 were tested.
HL-60 and Jurkat were p53 null leukemia cell lines while
K562 and NB-4 were p53-mutant leukemia cell lines.
Among them, HL-60 and NB-4 were acute promyelocy-
tic leukemia cell lines (the M3 subtype of AML). The
K562 was derived from a CML patient in blast crisis.
Jurkat was acute lymphoblastic leukemia cell line. Con-
sistent with the previous study in human tumor cell
lines, TIGAR was highly expressed in those p53 null or
mutant leukemia cell lines than in normal cells, particu-
larly for HL-60 cells (Fig. 2a, b). Therefore, HL-60 and
NB-4 acute promyelocytic leukemia cell lines were se-
lected for subsequent in vitro or in vivo experiments.
The K562 with a relative low expression of TIGAR was
also tested.
Table 1 Clinical characteristics of the patients with CN-AML
according to their TIGAR expression levels
TIGARhigh TIGARlow P
Age (years), median (range) 49 (15–80) 47 (12–86) 0.798
Gender, male/female 29/29 28/30 1.000
WBC, median (range) (×109/L) 26 (0.6–291) 34 (1.3–299) 0.995
Hb, median (range) (g/L) 79 (39–154) 87 (39–148) 0.398
PLT, median (range) (×109/L) 42 (10–190) 37 (2–295) 0.190
PB blasts (%), median (range) 66 (0–98) 65 (0–96) 0.525
BM blasts (%), median (range) 75 (11.6–96.2) 72 (24–93.6) 0.870
NPM1 (+) 25.0% (12/48) 22.0% (11/50) 0.726
CEBPA (+) 14.6% (7/48) 31.9% (15/47) 0.045
FLT3-ITD (+) 12.5% (6/48) 15.7% (8/51) 0.649
C-KIT (+) 6.3 (3/48) 6.3% (3/48) 1.000
p53 mutation 2.1% (1/48) 2.0%(1/51) 1.000
BM bone marrow, Hb hemoglobin, PB peripheral blood, PLT platelets,
WBC white blood cells







74 Idarubicin 12 mg/m2/day, IV,
day 1 to 3
CAG CAG 12 Aclarubicin 10 mg/day, IV,
day 1 to 8
DCAG DCAG 23 Aclarubicin 10 mg/day, IV,
day 3 to 6
IA: idarubucin 12 mg/m2 once daily intravenous (IV) from day 1 to 3 combined
with cytarabine 100 mg/m2 continuous intravenous (CIV) from day 1 to 7.
CAG: granulocyte colony-stimulating factor (G-CSF) of 300 μg/day (day 0–14)
subcutaneous injection (SQ) for priming combined with cytarabine of 10 mg/m2
SQ q12h for 14 days (day 1–14), aclarubicin of 10 mg/day IV for 8 days (day 1–8).
The G-CSF priming was discontinued if white blood count (WBC) was >20 × 109/L.
DCAG: decitabine of 15 mg/m2 IV for 5 days (day 1–5) and G-CSF of 300 μg/day
(day 0–9) SQ for priming combined with cytarabine of 10 mg/m2 SQ q12h for
7 days (day 3–9), aclarubicin of 10 mg/day IV for 4 days (day 3–6). The G-CSF
priming was discontinued if WBC was >20 × 109/L
Table 3 Multivariate analysis of factors associated with OS in
patients with CN-AML
B SE Wald P Exp (B) 95% CI
Age 0.039 0.017 5.017 0.025 1.040 1.005 to 1.076
WBC −0.004 0.004 1.250 0.264 0.996 0.989 to 1.003
Hb 0.008 0.009 0.769 0.381 1.008 0.990 to 1.027
PLT 0.003 0.003 1.242 0.265 1.003 0.997 to 1.009
PB blasts −0.006 0.011 0.326 0.568 0.994 0.972 to 1.016
BM blasts 0.029 0.015 3.584 0.058 1.030 0.999 to 1.061
Allo-SCT 0.323 0.614 0.277 0.599 0.724 0.217 to 2.411
NPM1 −0.197 0.432 0.209 0.648 0.821 0.352 to 1.914
CEBPA −0.880 0.543 2.620 0.106 0.415 0.143 to 1.204
FLT3-ITD −0.980 0.804 1.484 0.223 0.375 0.078 to 1.816
C-KIT −12.589 644.378 0.000 0.984 0.000
TIGAR 0.868 0.381 5.200 0.023 2.383 1.130 to 5.025
Chemotherapy 0.587 0.333 3.114 0.078 1.799 0.937 to 3.455
Allo-SCT allogeneic hematopoietic stem cell transplantation, BM bone marrow,
Hb hemoglobin, PB peripheral blood, PLT platelets, WBC white blood cells
The italicized number represented P < 0.05
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Next, we tested whether glycolysis may induce TIGAR
expression in human acute leukemia cells. CoCl2 was
used to stimulate glycolysis, and the glycolytic inhibitor
2-DG was used to block the glycolysis in leukemia cells
[24, 25]. We showed that CoCl2 increased the F2,6BP
while 2-DG reduced the F2,6BP in HL-60 cells
(Additional file 1: Figure S1). The effects of CoCl2 and
2-DG on the expression of TIGAR were also tested in
HL-60 and NB-4 cells. CoCl2 significantly increased
mRNA expression of TIGAR in both HL-60 and NB-4
cells (Fig. 2c). In contrast, the glycolytic inhibitor 2-DG
did not affect the expression of TIGAR in leukemia cells
(Fig. 2c). In addition, we validated that the expression of
TIGAR was induced by CoCl2 but not 2-DG, and the
CoCl2-induced expression of TIGAR was reversed by
TIGAR knockdown in HL-60 cells (Fig. 2d). We also
overexpressed TIGAR in K562 cells (TIGAR low
expressed acute leukemia cell line) and found that 2-DG
but not CoCl2 induced the expression of TIGAR in
K562 cells slightly (Fig. 2e). Neither 2-DG nor CoCl2
further increased the expression of TIGAR in TIGAR-
overexpressed K562 cells (Fig. 2e). Those results sug-
gested that some human acute leukemia cells showed a
high expression of TIGAR, and glycolysis may induce
the TIGAR expression in human leukemia cells.
TIGAR regulated the glycolysis through PFKFB3 in human
acute leukemia cells
Next, we investigated whether TIGAR regulated the gly-
colysis in leukemia cells. As most malignant cells were
highly glycolytic and produced high levels of ROS and
showed low levels of GSH, we first tested the effect of
TIGAR knockdown on ROS and GSH in leukemia cells.
We showed that knockdown of TIGAR reduced the
GSH level and increased the ROS level in NB-4 cells
(Fig. 3a). The similar results were also observed in
HL-60 cells (Fig. 3b). In contrast, we found that overex-
pression of TIGAR increased the GSH level and reduced
the ROS level in K562 cells (Fig. 3c). The potential mecha-
nisms of TIGAR regulating the glycolysis were also tested
Fig. 2 TIGAR showed a high expression in human leukemia cell lines, and glycolysis induced the expression of TIGAR. a, b TIGAR mRNA and
protein was compared among multiple leukemia cell lines and normal cells. c TIGAR mRNA level was compared by real time PCR in both HL-60
and NB-4 cells treated with or without CoCl2 and 2-DG. d Western blotting showed the expression of TIGAR in HL-60 cells with or without TIGAR
knockdown. e Western blotting showed the expression of TIGAR in K562 cells with or without TIGAR overexpression
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in leukemia cells. PFKFB3 was an important glycolytic ac-
tivator and active PFKFB3 induced PFK1 activity and led
to glycolysis in cancer cells (Additional file 2: Figure S2a).
Therefore, we determined to test whether TIGAR affected
the expression of PFKFB in leukemia cells. Knockdown of
TIGAR robustly increased the expression of PFKFB3 in
HL-60 cells while overexpression of TIGAR reduced the
expression of PFKFB3 in K562 cells (Additional file 2:
Figure S2b). Furthermore, we found that the AML drug
decitabine, hypomethylating DNA by inhibiting DNA
methyltransferase, significantly reduced the expression of
TIGAR while induced the expression of PFKFB3 in HL-60
cells (Additional file 2: Figure S2c). In addition, Cocl2
induced the TIGAR and reduced PFKFB3 while 2-DG
induced PFKFB3 in decitabine treated HL-60 cells
(Additional file 2: Figure S2c). Similarly, Cocl2 in-
duced TIGAR and reduced PFKFB3 in NB-4 cells
(Additional file 2: Figure S2d). Those results sug-
gested that PFKFB3 might also be a potential mechanism
of TIGAR regulating glycolysis in human leukemia
cells.
TIGAR knockdown inhibited the proliferation of leukemia
cells and sensitized leukemia cells to glycolysis inhibition
in vitro
As TIGAR showed a high expression in primary AML
cells and human acute leukemia cell lines, we next tested
whether TIGAR knockdown may affect the proliferation
of acute leukemia cells. Because TIGAR knockdown acti-
vated the glycolysis in leukemia cells, we also tested
whether the glycolysis inhibitor may show a combin-
ational effect with TIGAR knockdown. TIGAR shRNA
constructs by targeting distinct TIGAR sequence was
stably introduced into two different leukemia cell lines:
HL-60 and NB-4. We next tested whether TIGAR
knockdown affected the proliferation of HL-60 and
NB-4 cells. Knockdown of TIGAR significantly inhibited
the growth of both HL-60 and NB-4 cells (Fig. 4a, b). As
we showed that glycolysis inhibitor 2-DG did not affect
the expression of TIGAR, it suggested that 2-DG and
TIGAR may affect the leukemia glycolysis through differ-
ent mechanisms. Therefore, we tested whether TIGAR
knockdown had a combinational effect with glycolysis in-
hibitor: 2-DG. TIGAR shRNA but not NTC shRNA
showed a dramatically combination effect with 2-DG in
both HL-60 and NB-4 cells (Fig. 4a, b). In contrast,TIGAR
knockdown did not show any combinational effect with
CoCl2 (Fig. 4a, b). Next, we determined to understand the
potential mechanism of the combination effect of 2-DG
and TIGAR knockdown. Under normal conditions, HL-60
and NB-4 cells showed a high TIGAR protein expres-
sion and a low level of apoptosis. Knockdown of TIGAR
significantly increased leukemia cell apoptosis in both
HL-60 and NB-4 cell lines (Fig. 4c), indicating a potential
anti-apoptotic effect of TIGAR. CoCl2, inducting cell gly-
colysis, did not enhance the cell apoptosis in leukemia
cells with or without TIGAR knockdown. However, 2-DG
increased cell apoptosis in both leukemia cell lines. The
combination of 2-DG and TIGAR knockdown significantly
increased the leukemia cell apoptosis in comparison with
either 2-DG or TIGAR knockdown (Fig. 4c). We also
tested whether TIGAR knockdown led to the increase of
cell death/necrosis in 2-DG treated HL-60 or NB-4 cells.
We showed that TIGAR knockdown further enhanced the
Fig. 3 TIGAR regulated the glycolysis through PFKFB3 in leukemia cells. a, b TIGAR knockdown reduced the GSH level and increased the ROS level
in NB-4 cells (a) and HL-60 cells (b). c TIGAR overexpression increased the GSH level and reduced the ROS level in K562 cells
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percentage of cell death/necrosis in 2-DG-treated
leukemia cells (Additional file 3: Figure S3). These re-
sults suggested that TIGAR knockdown inhibited the
proliferation of HL-60 and NB-4 cells, and 2-DG-
caused glycolysis inhibition showed a synergistic effect
with TIGAR knockdown in inhibiting leukemia cell
proliferation.
TIGAR knockdown sensitizes HL-60 leukemia cells to
glycolysis inhibition in vivo
To further validate the effect of TIGAR knockdown on
leukemia cell proliferation, the effect of TIGAR knock-
down and TIGAR knockdown in combination with 2-
DG were tested in HL-60 xenograft mouse model.
TIGAR shRNA alone inhibited HL-60 cells growth by
around 45%, and the survival of AML mice was ex-
tended, and knockdown was confirmed (Fig. 5a–c). 2-
DG alone at tolerated dosage (10 mg/kg PO, qd) did not
inhibit HL-60 leukemia cell growth at the endpoint but
extended survival of AML mice mildly (Fig. 5a–c). More
strikingly, TIGAR knockdown and 2-DG combination
inhibited HL-60 cells growth by 59% and extended the
survival of HL-60 cells xenograft mice significantly
(Fig. 5a–c). TIGAR knockdown and 2-DG combination
also significantly reduced leukemia cells in the spleens
from HL-60 cells xenograft mice (Fig. 5d). We also
measured the apoptosis rates among different groups.
As expected, the combination of 2-DG and TIGAR
knockdown significantly increased the leukemia cell
apoptosis (Fig. 5e). These results suggest that TIGAR is
important for glycolysis of leukemia cells, and TIGAR
knockdown sensitizes human leukemia cells to glycolysis
inhibition both in vitro and in vivo.
The expression and functional effect of TIGAR were
uncoupled from p53 in HL-60 and NB-4 cells
p53 is disabled in HL-60 and NB-4 cell lines by either
deletion (HL-60) or missense mutation (NB-4) of the
p53 gene. As TIGAR was induced by p53 and protected
cancer cell from death, we next investigated whether the
expression or function of TIGAR may be affected by
overexpression p53 in leukemia cells. We stably trans-
fected with wild type p53 into leukemia cells and the
overexpression of p53 was confirmed by western blot
(Additional file 4: Figure S4). We found that TIGAR ex-
pression was mildly enhanced by p53 in both HL-60 and
NB-4 cells stably transfected with p53 (Fig. 6a, b). In
addition, TIGAR shRNA showed a better knockdown ef-
fect on leukemia cells transfected with p53. Those results
implied that TIGAR expression might be uncoupled from
p53 in leukemia cells.
We also examined whether overexpression of p53 may
affect the proliferation of human leukemia cells. Overex-
pression of p53 did not affect the proliferation of NB-4
cells. In contrast, MDM2 inhibitor Nutlin-3α is shown
to induce p53-mediated apoptosis [26] and showed a
Fig. 4 TIGAR knockdown inhibited the proliferation of leukemia cells and sensitized leukemia cells to glycolysis inhibition in vitro. a The cell
proliferation assay showed the cell growth of HL-60 cells with TIGAR knockdown in combination with Cocl2 or 2-DG. b The cell proliferation assay
showed the cell proliferation of NB-4 cells with TIGAR knockdown in combination with Cocl2 or 2-DG. c, d The cell apoptosis rate was determined
by FACS in both HL-60 (c) and NB-4 cells (d) with TIGAR knockdown in combination with Cocl2 or 2-DG. HL-60 and NB-4 cells with or without
TIGAR knockdown were treated with Cocl2 or 2-DG. The cells were collected on day 2 post Cocl2 or 2-DG treatment, and the apoptotic cells were
determined by FACS
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significant combinational effect with TIGAR knockdown
in NB-4 leukemia cells. TIGAR knockdown/Nutlin-3α/
p53 overexpression showed a best effect on inhibiting
leukemia cell proliferation (Fig. 6c). Consistent with
leukemia cell proliferation, leukemia cell apoptosis was
robustly increased by the combination of p53 overexpres-
sion, TIGAR knockdown, and Nutlin-3α in both HL-60
and NB-4 leukemia cells (Fig. 6d). In addition, the
inhibition of cell proliferation may be due to cell death/
necrosis. We also measured the cell death/necrosis and
showed that the cell death/necrosis rate was relatively low
among the different groups (Additional file 5: Figure S5).
These results suggested that overexpression of p53 only
slightly affected TIGAR expression in human leukemia
cells, and p53 activation had a combinational effect on
inhibiting leukemia cell proliferation and promoting
leukemia cell apoptosis.
Discussion
Intracellular processes drived multiple hallmarks of can-
cer have highlighted the potential to affect oncogenesis
and cancer progression by manipulating these critical
processes at a molecular level [27]. In our study, the
prognostic relevance of TIGAR expression in patients
with CN-AML, suggested that higher TIGAR expression
might be an independent poor prognostic factor,
Fig. 5 TIGAR knockdown sensitized HL-60 leukemia cells to glycolysis inhibition in vivo. a Western blotting analysis of HL-60 xenograft tumor
samples. The ascites-derived tumor cells from mice were collected and lysed at the end of the study, and western blotting analyses of TIGAR and
TUBULIN were performed (n = 2 for each group). b The survival of HL-60 xenograft mice with the combined treatment of TIGAR knockdown and
2-DG. 1 × 106 HL-60 cells with or without TIGAR knockdown were inoculated into BALB/c (nu/nu) nude mice (n = 10). Those mice were treated or
untreated with 2-DG (2 g/kg, PO, QD) from 1-week post implantation of HL-60 cells. c In HL-60 xenograft tumor mice, the effectiveness of TIGAR
knockdown in combination with 2-DG in treating HL-60 xenograft tumor mice correlated with decreased percentages of HL-60 leukemia cells in
PB. FACS analysis showed the decrease of HL-60 cells in PB of HL-60 xenograft tumor mice. Mean ± SD was shown. d Photomicrographs of
hematoxylin and eosin-stained spleen sections from HL-60 xenograft tumor mice with the combined treatment of TIGAR knockdown and 2-DG.
e The combined treatment of TIGAR knockdown and 2-DG induced apoptosis of HL-60 leukemia cells in mice. The HL-60 cells from ascites fluid
were collected and stained with PI and Annexin-V, and the percentages of PI−/Annexin-V+, representing apoptotic cells, were determined by FACS
(n = 5). Mean ± SD was shown
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irrespective of age, WBC count, karyotype, and other gen-
etic markers. Chemotherapy regimen was also an important
factor to affect the outcome of AML patients. In our study,
three chemotherapy regimens were used among AML pa-
tients with high or low TIGAR expression. The multivariate
analysis showed that these chemotherapy regimens (P =
0.078) as well as BM blast (P = 0.058) may also affect the
outcome of patients with CN-AML. Furthermore, high ex-
pression of TIGAR showed an anti-apoptotic effect on hu-
man leukemia cells, which may contribute to the poor OS
and higher cumulative incidence of relapse in patients
with CN-AML treated with chemotherapy. The relation-
ship between TIGAR expression and prognosis in patients
with solid cancers was also shown in multiple studies [11,
15, 28]. Similar with human acute leukemia cells, the in-
creased expression of TIGAR was able to protect against
metabolic stress, contributes to tumor growth, and be
uncoupled from its normal dependence on p53 in several
cancer cell types [4]. A number of genetic alterations seen
in CN-AML patients with possible prognostic relevance
(DNMT3A, IDH1/2, TET2) are not considered here, and
the correlation of TIGAR expression and outcome may
not be independent of other variables in CN-AML. In
addition, TIGAR knockdown enhanced the radiosensitivity
of cancer cells, suggesting that correlation of TIGAR ex-
pression and outcome of patients with CN-AML may also
depend on the response of AML cells to chemotherapy
[13]. In the future, it will be important to understand how
Fig. 6 TIGAR expression and its anti-apoptotic effect were uncoupled from p53 in human leukemia cells. a Real-time PCR showed that the mRNA
expression of TIGAR was not affected by p53 overexpression in both HL-60 and NB-4 cells. b Western blotting showed that the protein expression
of TIGAR was not affected by p53 overexpression in both HL-60 and NB-4 cells. c The cell proliferation assay showed the cell growth of NB-4 cells
with TIGAR knockdown in combination with p53 overexpression or/and MDM2 inhibitor Nutlin-3α. d TIGAR knockdown in combination with p53
overexpression or/and MDM2 inhibitor Nutlin-3α induced the apoptosis of NB-4 and HL-60 cells in vitro
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TIGAR affects the response of leukemia cells to chemo-
therapy or targeted therapy.
TIGAR might have a dual effect on the proliferation of
leukemia cell (Fig. 7). On the one hand, TIGAR inhibited
glycolysis through PFKFB3 in leukemia cells [29].
TIGAR inhibited glycolysis, decreased ROS, and in-
creased GSH levels. Knockdown of TIGAR induced
while overexpression of TIGAR reduced the expression
of glycolysis activator PFKB3 in leukemia cells. High
levels of glycolysis in cancer cells have been linked to
poor prognosis and chemotherapy resistance [30, 31].
Highly glycolytic AML blasts are more resistant to com-
bined all-trans retinoic acid and arsenic trioxide treat-
ment than moderately glycolytic blasts [31]. Therefore,
high expression of TIGAR inhibited the glycolysis of
leukemia cells and led leukemia cells to sensitive to
chemotherapy. On the other hand, our results also
showed that TIGAR protected leukemia cells from cell
death. Knockdown of TIGAR led a significant increase of
cell apoptosis in human leukemia cells. In contrast,
TIGAR knockdown also promoted the glycolysis in
leukemia cells. Our studies showed that TIGAR related
anti-apoptosis and lower glycolysis might maintain a
steady-state. Our results also showed that glycolysis in-
hibition or TIGAR knockdown alone only caused the
limited apoptosis of leukemia cells. In contrast, a robust
leukemia cell apoptosis was observed when leukemia
cells with simultaneous impairment of TIGAR expres-
sion and glycolysis. In addition, TIGAR knockdown in
combined with 2-DG also mildly enhanced cell death/
necrosis of leukemia cells. The mechanism of TIGAR
regulating the cell apoptosis or necrosis and glycolysis of
leukemia cells was still not clear. More studies should be
done to illustrate the underlying process.
TIGAR might be a novel target for treating human
acute leukemia. Knockdown of TIGAR inhibited the pro-
liferation of human leukemia cells and sensitized
leukemia cells to glycolysis inhibitor 2-DG both in vitro
and in vivo. In addition, TIGAR knockdown in combin-
ation with 2-DG led leukemia cells to apoptosis. As sup-
pressing glycolysis with inhibitors was not effective at
killing tumor cells, its combination with other tumor-
specific metabolic inhibitors may be necessary for thera-
peutic intervention [32]. Silencing TIGAR also enhanced
the radiosensitivity of U87MC and glioma cells [13]. Our
findings suggest that combining glycolytic inhibitors
with a potential TIGAR inhibitor and current standard
chemotherapy may be a powerful and effective treatment
for not only human leukemia but also other cancer
types. More efforts are needed to develop the potent and
specific small molecule compound for TIGAR.
However, TIGAR expression and its anti-apoptotic ef-
fect were uncoupled from p53 in human leukemia cells.
In normal cells, TIGAR transcription was rapidly acti-
vated by p53 in response to low levels of cellular stress.
In human tumor cells, the expression of TIGAR was
regulated by p53 dependent or p53-independent mecha-
nisms [8]. In wild-type p53 tumor cell line, the basal
Fig. 7 A working model of TIGAR regulating the glycolysis and the proliferation of human leukemia cells. TIGAR played a dual role in human AML
cells. It protected the leukemia cells from cell death while inhibited PFKFB3-regulated glycolysis in AML. Thus, TIGAR knockdown or decitabine induced
apoptosis of leukemia cells through inhibiting the expression of TIGAR and sensitized leukemia cells to glycolysis inhibition in human AML
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expression of TIGAR was relatively low and the induc-
tion of p53 led to an increased expression of TIGAR
protein [8]. However, p53 null or mutant human tumor
cell lines including H1299, U2OS, and RKO showed a
significant basal level of TIGAR protein expression,
which indicated the existence of p53-independent mech-
anisms to regulate TIGAR expression in human cancer
cells [8]. In human p53 null or mutant leukemia cells,
overexpression of p53 did not significantly induce the
expression of TIGAR. Our observation was also sup-
ported by other studies, which also showed that TIGAR
expression was regulated by other non-p53 mechanisms
in human cancer cell line [8, 33, 34].
Conclusions
In summary, our study showed that high TIGAR expres-
sion was associated with poor survival and a high inci-
dence of relapse in adult patients with CN-AML, even
after adjustment for known clinical and common molecu-
lar risk factors. Moreover, sustained TIGAR activation,
uncoupled from p53, may support AML cell growth and
survival. TIGAR in cooperation with glycolysis had a
strong anti-apoptotic effect in AML cells. Therefore, the
combination of TIGAR inhibitors with anti-glycolytic
agents may be powerful novel therapies for the future clin-
ical use in AML patients.
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